Items tagged with Drug-resistant TB
South Africa: New TB drug gets ‘fast-track status’ (post)
Cape Town - Patients with multidrug-resistant (MDR) tuberculosis could soon have access to a promising new drug – Bedaquiline – as the Medicines Control Council (MCC) is “fast-tracking” its authorisation processes to have the drug licensed.
Training course Strengthening TB Control in prisons of M/XDR-TB high-burden countries (post)
The newly-appointed WHO Collaborating Centre on Prevention and Control of Tuberculosis in Prisons located in Azerbaijan, is organizing a training course for policy makers and health providers involved in planning and implementation of tuberculosis services in penal institutions of Eastern Europe and Central Asia. The course will take place in Baku, Azerbaijan on 22 - 26 September 2014. Only 15 participants can be accepted. Applications should be sent by 1 August 2014 through the link below.
Patient support interventions to improve adherence to drug resistant tuberculosis (DR-TB) treatment - a counseling toolkit (post)
25 June 2014 - Khayelitsha, South Africa - Khayelitsha, a township in the Western Cape, South Africa, is home to approximately 500,000 residents and has some of the highest rates of HIV and tuberculosis globally. In response to the growing burden of drug-resistant tuberculosis (DR-TB) in Khayelitsha, Medecins Sans Frontieres (MSF), in collaboration with the City of Cape Town Health and the Provincial Government of the Western Cape, began piloting a decentralized model of care for DR-TB in 2007. The patient-centered, community-based model was thereafter implemented in 10 primary health care clinics (PHC) within the sub-district, and is now managed in its entirety by the local Department of Health. In 2011, various aspects of this decentralized model were adopted and implemented across other sub-districts in Cape Town as well as other provinces in South Africa.
Research may yield new ways to treat antibiotic-resistant TB (post)
CORVALLIS, Ore. – Scientists in the United States and India have successfully modified the precursor to one of the drugs used to treat tuberculosis, an important first step toward new drugs that can transcend antibiotic resistance issues that experts consider a serious threat to global health.
Brook Baker: MSF victorious in overcoming registration barrier to important 2d line treatment of DR-TB, but patent barrier may last a little bit longer (post)
Médecins Sans Frontières has obtained an important but long-delayed victory in a a challenge to the refusal of the Medicines Control Council in South Africa to issue section 21 permission allowing the temporary importation and patient use of a generic version of a key, tuberculosis medicine, linezolid. Linezolid can be effectively used as a treatment of drug-resistant tuberculosis, but the private sector cost of taking one pill a day for two years was approximately $49,000 when the medicine was sourced from the brand-name patent holder, Pfizer, at $65/pill. Generic versions of linezolid are manufactured in India by Hetero at significantly reduced cost of only $8/pill.
TB drug resistance signifies failure (post)
LONDON, 9 July 2014 (IRIN) - Tuberculosis control programmes are among the oldest public health campaigns (dating back 125 years) but are not nearly as successful as they should be. Despite effective drugs having been available for over 50 years, TB still kills a million people a year, making it the world's single deadliest infectious disease after AIDS.
The dangerous resurgence of tuberculosis in China (post)
China now has the second largest tuberculosis epidemic -second only to India- with more than 1.3 million new cases of tuberculosis every year. What makes the situation particularly serious, however, is that, according to the Chinese Center for Disease Control, China has the largest number of patients with Multiple Drug Resistant Tuberculosis (MDR-TB), and that Extremely Resistant Drug Tuberculosis (XDR-TB) is also widespread. These facts show the need to step up efforts to combat the disease.
Video: South Africa’s shrinking options for drug-resistant TB (post)
Tuberculosis is the leading cause of death in South Africa due, in part, to the high prevalence of HIV. Today, the country faces the additional problem of TB bacteria becoming resistant to all available antibiotics. Doctors are running out of treatment options and, as they await new drugs and vaccines, reducing transmission becomes a crucial component of disease control. The following audio slideshow investigates the problem in the townships of Cape Town.
India: Study finds doctors also adding to burden of drug-resistant TB cases (post)
PUNE: It is not just the patients who default on treatment, but also private doctors who are to blame for the rise in drug-resistant cases of tuberculosis.
Novel TB regimen could reduce treatment duration (post)
A novel TB drug regimen could treat drug-sensitive and some forms of drug-resistant TB far more quickly than current standard TB therapy, according to findings from a phase IIb trial were presented today at the 20th International AIDS Conference (AIDS 2104) in Melbourne, Australia.
Page 6 of 117 · Total posts: 0
←First 5 6 7 Last→